A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
Clinical trial NCT07391657 · RECRUITING
Trial details
- NCT number
- NCT07391657
- Sponsor
- AstraZeneca
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2026-02-23
- Primary completion
- 2028-06-14
- Enrollment
- 508
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.